Document is current
Any future updates will be listed below
-
Authors
Brändl, Björn https://orcid.org/0000-0003-1044-1355
Steiger, Mara https://orcid.org/0000-0002-3747-685X
Kubelt, Carolin
Rohrandt, Christian
Zhu, Zhihan https://orcid.org/0000-0003-3779-4265
Evers, Maximilian
Wang, Gaojianyong
Schuldt, Bernhard
Afflerbach, Ann-Kristin
Wong, Derek
Lum, Amy
Halldorsson, Skarphedinn
Djirackor, Luna
Leske, Henning
Magadeeva, Svetlana
Smičius, Romualdas
Quedenau, Claudia https://orcid.org/0000-0002-6846-4915
Schmidt, Nils O.
Schüller, Ulrich https://orcid.org/0000-0002-8731-1121
Vik-Mo, Einar O. https://orcid.org/0000-0001-8303-4123
Proescholdt, Martin
Riemenschneider, Markus J.
Zadeh, Gelareh https://orcid.org/0000-0002-6637-4502
Ammerpohl, Ole
Yip, Stephen https://orcid.org/0000-0002-8514-9861
Synowitz, Michael
van Bömmel, Alena https://orcid.org/0000-0002-8434-8586
Kretzmer, Helene https://orcid.org/0000-0002-0723-4980
Müller, Franz-Josef https://orcid.org/0000-0001-9478-8430
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (13GW0347C, 13GW0347C, 13GW0347C, 13GW0347D, 13GW0347D, 13GW0347A)
- License Information
-
More Information
Article History
Received: 7 February 2024
Accepted: 27 November 2024
First Online: 28 February 2025
Competing interests
: F.-J.M., B.S., H.K., A.v.B., B.B. and C.R. filed a patent application (WO 2023/031485 A1) covering the development of MethyLYZR. S.Y. is a member of advisory boards and has received honoraria from Amgen, AstraZeneca, Bayer, Janssen, Roche and Servier. H.K. is a member of an expert panel and has received honoraria from Roche and Oxford Nanopore Technologies. The remaining authors declare no competing interests.
